Kartos Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Redwood Citycaliforniawith Additional Operations In Bellevuewashingtonfounded In 2018The Company Focuses On Developing Targeted Therapies For Hematologic And Oncologic Conditionswith A Team Of Approximately 75 Professionalskartos Emphasizes Innovation And Collaboration In Cancer Therapeutics The Company Specializes In Small Molecule Drug Developmentfeaturing A Pipeline That Includes Navtemadlinkrt 232 A Clinical Stage Mdm2 Inhibitor In Phase 2 3 Trials For Recurrent Endometrial Cancer And Other Malignanciesand M 7583A Btk Inhibitor In Phase 2 Development For Post Essential Thrombocythemia Myelofibrosiskartos Leverages Its Expertise In Mdm2 And Btk Inhibition To Advance Its Clinical Programswhich Include Both Internally Developed Compounds And In Licensed Assets
